Biocept (FRA:B00) 3-Year EBITDA Growth Rate : 46.50% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept 3-Year EBITDA Growth Rate?

Biocept's EBITDA per Share for the three months ended in Jun. 2023 was €-2.86.

During the past 3 years, the average EBITDA Per Share Growth Rate was 46.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 74.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biocept was 91.20% per year. The lowest was 45.60% per year. And the median was 64.45% per year.

Competitive Comparison of Biocept's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Biocept's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocept's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Biocept's 3-Year EBITDA Growth Rate falls into.

Biocept 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Biocept (FRA:B00) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Biocept 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Biocept's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines